Search

Your search keyword '"Cairo, Mitchell S."' showing total 43 results

Search Constraints

Start Over You searched for: Author "Cairo, Mitchell S." Remove constraint Author: "Cairo, Mitchell S." Publisher elsevier Remove constraint Publisher: elsevier
43 results on '"Cairo, Mitchell S."'

Search Results

2. Contributors

3. Contributors

4. Lymphoma

6. Contributors

7. Contributors

10. Contributors

11. List of Contributors

13. CONTRIBUTORS

15. Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: Results of a modified Delphi panel.

17. Diagnosis and management of mature B-cell lymphomas in children, adolescents, and young adults.

18. Cellular and humoral immunotherapy in children, adolescents and young adults with non-Hodgkin lymphoma.

20. KIR-favorable TCR-αβ/CD19-depleted haploidentical HCT in children with ALL/AML/MDS: primary analysis of the PTCTC ONC1401 trial.

21. A new Burkitt "look-alike" lymphoma.

22. A Clinical and Economic Comparison of Rasburicase and Allopurinol in the Treatment of Patients With Clinical or Laboratory Tumor Lysis Syndrome.

23. Upregulation of NKG2D ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity.

24. Humoral and cellular immunotherapy in ALL in children, adolescents, and young adults.

25. Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens.

26. Outcome and pathologic classification of children and adolescents with mediastinal large B-cell lymphoma treated with FAB/LMB96 mature B-NHL therapy.

27. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?

28. Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling.

29. Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease.

30. Interleukin (IL)-15 in combination with IL-2, fms-like tyrosine kinase-3 ligand and anti-CD3 significantly enhances umbilical cord blood natural killer (NK) cell and NK-cell subset expansion and NK function.

31. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis.

32. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States.

33. Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related, or matched unrelated donors.

34. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia.

35. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.

36. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents.

37. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.

38. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry.

39. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.

40. A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma.

41. B large-cell lymphoma in children and adolescents.

42. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling.

43. Liposomal amphotericin B (AmBisome) compared with amphotericin B +/- FMLP induces significantly less in vitro neutrophil aggregation with granulocyte-colony-stimulating factor/dexamethasone-mobilized allogeneic donor neutrophils.

Catalog

Books, media, physical & digital resources